Free Trial
→ ‘Please’: OpenAI CEO Sam Altman Begs Small Company for Help (From Altimetry) (Ad)tc pixel Free QLGN Stock Alerts

Qualigen Therapeutics (QLGN) Competitors

Qualigen Therapeutics logo
$1.44 +0.02 (+1.41%)
As of 05/6/2026
Compare

QLGN vs. BON, MTEX, GNPX, LIMN, and NCNA

Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Bon Natural Life (BON), Mannatech (MTEX), Genprex (GNPX), Liminatus Pharma (LIMN), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to Bon Natural Life?

Qualigen Therapeutics (NASDAQ:QLGN) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Bon Natural Life N/A N/A N/A

Bon Natural Life has higher revenue and earnings than Qualigen Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
Bon Natural Life$18.67M0.53-$2MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Bon Natural Life. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Bon Natural Life Neutral

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Bon Natural Life beats Qualigen Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Mannatech?

Qualigen Therapeutics (NASDAQ:QLGN) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -14.08%. Qualigen Therapeutics' return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Mannatech -14.08%-398.35%-45.63%

Qualigen Therapeutics has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
Mannatech$108.04M0.08-$15.21M-$8.00N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Qualigen Therapeutics and Mannatech tied by winning 5 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Genprex?

Qualigen Therapeutics (NASDAQ:QLGN) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Genprex. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Genprex Neutral

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Qualigen Therapeutics' return on equity of 0.00% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Genprex N/A -464.05%-275.54%

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
GenprexN/AN/A-$16.23M-$26.50N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Qualigen Therapeutics beats Genprex on 7 of the 9 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Liminatus Pharma is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liminatus PharmaN/AN/A-$10.21M-$0.15N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

Company Net Margins Return on Equity Return on Assets
Liminatus PharmaN/A N/A -402.52%
Qualigen Therapeutics N/A N/A -202.16%

3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Overall Sentiment
Liminatus Pharma Neutral
Qualigen Therapeutics Neutral

Summary

Qualigen Therapeutics beats Liminatus Pharma on 6 of the 7 factors compared between the two stocks.

How does Qualigen Therapeutics compare to NuCana?

NuCana (NASDAQ:NCNA) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A-$38.71M-$127.73N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

Qualigen Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
NuCanaN/A -189.94% -130.93%
Qualigen Therapeutics N/A N/A -202.16%

NuCana has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

44.0% of NuCana shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuCana
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, NuCana and NuCana both had 1 articles in the media. NuCana's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NuCana
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

NuCana beats Qualigen Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QLGN vs. The Competition

Export
MetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.44M$3.17B$6.31B$12.15B
Dividend YieldN/A1.87%2.78%5.25%
P/E Ratio-0.1917.5228.4527.00
Price / SalesN/A301.93535.2976.97
Price / CashN/A56.3043.3053.97
Price / Book-0.354.319.836.89
Net Income-$6.26M$72.19M$3.55B$333.11M
7 Day PerformanceN/AN/AN/A0.14%
1 Month Performance5.11%4.32%5.22%6.78%
1 Year Performance-59.90%46.57%40.40%38.93%

Qualigen Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QLGN
Qualigen Therapeutics
0.0067 of 5 stars		$1.44
+1.4%		N/A-59.6%$2.44MN/AN/A50
BON
Bon Natural Life
0.3215 of 5 stars		$1.18
-7.7%		N/AN/A$9.58M$18.67MN/A100
MTEX
Mannatech
0.1253 of 5 stars		$4.88
+2.7%		N/A-54.0%$9.42M$108.04MN/A250
GNPX
Genprex
0.1284 of 5 stars		$0.89
+0.6%		N/A-93.8%$9.28MN/AN/A20
LIMN
Liminatus Pharma
0.2948 of 5 stars		$0.21
-1.4%		N/AN/A$9.20MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel
I’m sounding the alarm
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel